Table 5.
Multivariate odds of BO compared with screening colonoscopy controls, adjusted for other IGF biomarkers (lowest tertile set as baseline)
| Tertile
| ||||
|---|---|---|---|---|
| 1 | 2 | 3 | p Value (trend)* | |
| IGF-1 | ||||
| Range, ng/ml | <94.48 | 94.48–130.98 | >130.99 | <0.0001 |
| Cases | 33 | 24 | 76 | |
| Controls | 311 | 310 | 311 | |
| OR (95% CI) | 1.0 (referent) | 3.27 (1.26 to 8.45) | 10.5 (4.02 to 27.3) | |
| IGFBP-1 | ||||
| Range, ng/ml | <13.2 | 13.92–31.49 | >31.49 | <0.0001 |
| Cases | 91 | 32 | 10 | |
| Controls | 318 | 306 | 308 | |
| OR (95% CI) | 1.0 (referent) | 0.40 (0.20 to 0.78) | 0.16 (0.06 to 0.40) | |
| IGFBP-3 | ||||
| Range, ng/ml | <3286 | 3286–4020 | >4020 | <0.0001 |
| Cases | 81 | 36 | 16 | |
| Controls | 313 | 309 | 310 | |
| OR (95% CI) | 1.0 (referent) | 0.41 (0.20 to 0.83) | 0.05 (0.01 to 0.14) | |
*
Adjusted for age, gender, race (Caucasian vs other) and waist-to-hip ratio.
BO, Barrett’s oesophagus; GORD, gastro-oesophageal reflux disease; IGF-1, insulin growth factor 1; IGFBP-1, IGFBP-3, IGF binding proteins 1 and 3.